ciprofloxacin has been researched along with Keratitis in 94 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Keratitis: Inflammation of the cornea.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Topical ciprofloxacin offers a therapeutic alternative for nontuberculous mycobacterial keratitis, which was refractory to amikacin treatment." | 9.08 | Topical ciprofloxacin for treating nontuberculous mycobacterial keratitis. ( Hu, FR; Luh, KT, 1998) |
| "A multicenter, prospective clinical study of 148 culture-proven cases of bacterial keratitis, treated with ciprofloxacin 0." | 9.07 | Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for treatment of bacterial keratitis. ( Leibowitz, HM, 1991) |
| "Literature searches were made in Medline and Pubmed using the search terms [Pseudomonas] or [Staphylococcus] and [fluoroquinolone] or [cephalosporin] or [gentamicin] and [keratitis] or [cornea]." | 8.87 | Review of resistance of ocular isolates of Pseudomonas aeruginosa and staphylococci from keratitis to ciprofloxacin, gentamicin and cephalosporins. ( Willcox, MD, 2011) |
| "This article reports on comparative in vitro characterization and in vivo evaluation of pre-formed cellulose-based gels, methylcellulose (MC) and carboxymethylcellulose sodium (CMC) and in situ gel-forming Pluronic F127 (PL) for ocular delivery of ciprofloxacin hydrochloride (Cipro) by using a bacterial keratitis model and histological corneal examination." | 7.81 | Comparative studies for ciprofloxacin hydrochloride pre-formed gels and thermally triggered (in situ) gels: in vitro and in vivo appraisal using a bacterial keratitis model in rabbits. ( Abdelkader, H; Mansour, HF, 2015) |
| "To report a case of microbial keratitis caused by Nocardia transvalensis with resistance to amikacin." | 7.74 | Nocardia transvalensis resistant to amikacin: an unusual cause of microbial keratitis. ( Pandya, VB; Petsoglou, C, 2008) |
| " aureus keratitis, following the treatments, the median number of CFU of recoverable bacteria for chlorhexidine (n = 10), ciprofloxacin (n = 12), tobramycin/cefazolin (n = 12), and controls (n = 10) was 1." | 7.74 | A comparison of topical chlorhexidine, ciprofloxacin, and fortified tobramycin/cefazolin in rabbit models of Staphylococcus and Pseudomonas keratitis. ( Bouchard, CS; Bu, P; Carey, R; Riske, PS; Zaya, NE, 2007) |
| "Taurolidine is a broad-spectrum, non antibiotic antimicrobial agent, not previously tested against the common causes of bacterial keratitis." | 7.73 | Effectiveness of topical taurolidine versus ciprofloxacin, ofloxacin, and fortified cefazolin in a rabbit Staphylococcus aureus keratitis model. ( Gurkan, T; Oguz, E; Oguz, H; Ozbilge, H, 2005) |
| "Both moxifloxacin and ciprofloxacin performed significantly better than control in the treatment of Pseudomonas aeruginosa keratitis (P=0." | 7.73 | Comparative efficacy of topical moxifloxacin versus ciprofloxacin and vancomycin in the treatment of P. aeruginosa and ciprofloxacin-resistant MRSA keratitis in rabbits. ( Aliprandis, E; Ciralsky, J; Herling, I; Katz, HR; Lai, H, 2005) |
| "The purpose of this study was to quantitatively compare, in a rabbit keratitis model, the levels of effectiveness of moxifloxacin, levofloxacin, and ciprofloxacin for the treatment of Staphylococcus aureus isolates of diverse antibiotic susceptibilities." | 7.72 | Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis. ( Dajcs, JJ; Girgis, DO; Marquart, ME; O'Callaghan, RJ; Thibodeaux, BA; Traidej, M, 2004) |
| "Occurrence of a white precipitate of the corneal surface was recorded among 624 patients with presumed bacterial keratitis who were treated with topical ciprofloxacin 0." | 7.72 | Corneal ciprofloxacin precipitation during bacterial keratitis. ( Abshire, RL; Wilhelmus, KR, 2003) |
| " In this study we investigate the emergence of fluoroquinolone (ciprofloxacin, levofloxacin) resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis." | 7.72 | Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis. ( Alfonso, EC; Marangon, FB; Miller, D; Muallem, MS; Romano, AC, 2004) |
| " aureus to many antibiotics including ciprofloxacin and highlights the need for an alternative to ciprofloxacin monotherapy for the treatment of staphylococcal keratitis." | 7.72 | Clinical resistance of Staphylococcus keratitis to ciprofloxacin monotherapy. ( Garg, P; Rao, GN; Sharma, S; Sharma, V, 2004) |
| "Lomefloxacin was compared with ciprofloxacin in different rabbit keratitis models." | 7.71 | Lomefloxacin is an effective treatment of experimental bacterial keratitis. ( Gordon, YJ; Kowalski, RP; Romanowski, EG; Yates, KA, 2001) |
| "We compared levofloxacin with ciprofloxacin and ofloxacin using the in vitro susceptibilities of Staphylococcus aureus (SA) and Pseudomonas aeruginosa (PA) keratitis isolates." | 7.71 | An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa. ( Gordon, YJ; Husted, RC; Karenchak, LM; Kowalski, RP; Pandya, AN; Ritterband, DC; Romanowski, EG; Shah, MK, 2001) |
| "Topical treatment of experimental Staphylococcus keratitis with ciprofloxacin-PSS, ciprofloxacin, or ofloxacin was effective." | 7.70 | Effectiveness of ciprofloxacin-polystyrene sulfonate (PSS), ciprofloxacin and ofloxacin in a Staphylococcus keratitis model. ( Engel, LS; Green, LC; Hill, JM; Moreau, JM; O'Callaghan, RJ, 1998) |
| "By use of the in vitro antimicrobial susceptibility test, 22 cases of keratitis caused by ciprofloxacin-resistant Pseudomonas were identified." | 7.70 | Ciprofloxacin-resistant Pseudomonas keratitis. ( Garg, P; Rao, GN; Sharma, S, 1999) |
| "36%) tobramycin for the treatment of methicillin-sensitive and methicillin-resistant Staphylococcus aureus keratitis during early and late stages of infection." | 7.69 | Ciprofloxacin versus tobramycin for the treatment of staphylococcal keratitis. ( Callegan, MC; Engel, LS; Hill, JM; O'Callaghan, RJ, 1994) |
| "To compare the efficacy of ciprofloxacin hydrochloride ointment with that of ciprofloxacin drops for treatment of experimental Pseudomonas keratitis, rabbit eyes were infected by intrastromal injection of 10(3) colony-forming units (CFU) log-phase P." | 7.68 | Ciprofloxacin ointment versus ciprofloxacin drops for therapy of experimental Pseudomonas keratitis. ( Hill, JM; Hobden, JA; Insler, MS; O'Callaghan, RJ, 1993) |
| "36% tobramycin in two experimental models of keratitis, using a methicillin-sensitive strain of Staphylococcus aureus and an aminoglycoside-sensitive strain of Pseudomonas aeruginosa, respectively." | 7.68 | Topical ciprofloxacin versus topical fortified antibiotics in rabbit models of Staphylococcus and Pseudomonas keratitis. ( Cohen, KL; Lauffenburger, MD, 1993) |
| "Studies using ciprofloxacin for the therapy of experimental aminoglycoside-resistant keratitis caused by Pseudomonas aeruginosa were conducted using transcorneal iontophoresis as the drug-delivery system." | 7.68 | Ciprofloxacin iontophoresis for aminoglycoside-resistant pseudomonal keratitis. ( Hill, JM; Hobden, JA; Insler, MS; O'Callaghan, RJ; Reidy, JJ, 1990) |
| "Ciprofloxacin is a fluoroquinolone antimicrobial agent inhibiting bacterial DNA gyrase, with good in vitro and in vivo activity against many Gram-positive and Gram-negative ocular pathogens." | 6.68 | Clinical evaluation of ciprofloxacin ophthalmic solution in the treatment of refractory bacterial keratitis. ( Chang, SW; Hu, FR; Tsai, AC; Tseng, MC, 1995) |
| "Ciprofloxacin is a potent fluoroquinolone antibiotic with in vitro activity against many significant gram-positive and gram-negative ocular pathogens." | 6.38 | Insights from experimental data on ciprofloxacin in the treatment of bacterial keratitis and ocular infections. ( Cokingtin, CD; Hyndiuk, RA, 1991) |
| "Ciprofloxacin is a fluoroquinolone antibiotic with broad spectrum bactericidal activity." | 5.29 | The effectiveness of two ciprofloxacin formulations for experimental Pseudomonas and Staphylococcus keratitis. ( Callegan, MC; Engel, LS; Folkens, AT; Hill, JM; O'Callaghan, RJ; Shimomura, Y, 1996) |
| "Ciprofloxacin is a new quinolone antibiotic that is highly active in vitro against Pseudomonas aeruginosa." | 5.27 | Topical ciprofloxacin treatment of Pseudomonas keratitis in rabbits. ( Dick, JD; Gottsch, JD; O'Brien, TP; Sawusch, MR, 1988) |
| "Bacterial keratitis (BK) presentations are often treated using the commercially available second-generation fluoroquinolones ciprofloxacin 0." | 5.22 | The clinical treatment of bacterial keratitis: A review of drop instillation regimes. ( Essex, RW; Maddess, T; Pearce, JG, 2022) |
| "Topical ciprofloxacin offers a therapeutic alternative for nontuberculous mycobacterial keratitis, which was refractory to amikacin treatment." | 5.08 | Topical ciprofloxacin for treating nontuberculous mycobacterial keratitis. ( Hu, FR; Luh, KT, 1998) |
| "A multicenter, prospective clinical study of 148 culture-proven cases of bacterial keratitis, treated with ciprofloxacin 0." | 5.07 | Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for treatment of bacterial keratitis. ( Leibowitz, HM, 1991) |
| "Literature searches were made in Medline and Pubmed using the search terms [Pseudomonas] or [Staphylococcus] and [fluoroquinolone] or [cephalosporin] or [gentamicin] and [keratitis] or [cornea]." | 4.87 | Review of resistance of ocular isolates of Pseudomonas aeruginosa and staphylococci from keratitis to ciprofloxacin, gentamicin and cephalosporins. ( Willcox, MD, 2011) |
| " When 13 strains were tested for tolerance against ciprofloxacin, the most commonly used monotherapy for keratitis, one had high tolerance and nine had medium tolerance." | 4.31 | Ciprofloxacin resistance and tolerance of Pseudomonas aeruginosa ocular isolates. ( Khan, M; Ma, K; Wan, I; Willcox, MD, 2023) |
| "Ciprofloxacin (CIP) was effective in treating bacterial keratitis." | 3.81 | Preparation and in vivo evaluation of in situ gel system as dual thermo-/pH-responsive nanocarriers for sustained ocular drug delivery. ( Alimohammadi, S; Davaran, S; Lotfipour, F; Salehi, R; Sedghipour, MR; Sedghipour, N, 2015) |
| "This article reports on comparative in vitro characterization and in vivo evaluation of pre-formed cellulose-based gels, methylcellulose (MC) and carboxymethylcellulose sodium (CMC) and in situ gel-forming Pluronic F127 (PL) for ocular delivery of ciprofloxacin hydrochloride (Cipro) by using a bacterial keratitis model and histological corneal examination." | 3.81 | Comparative studies for ciprofloxacin hydrochloride pre-formed gels and thermally triggered (in situ) gels: in vitro and in vivo appraisal using a bacterial keratitis model in rabbits. ( Abdelkader, H; Mansour, HF, 2015) |
| "These novel contact lenses designed for the extended release of ciprofloxacin may be beneficial to supplement or augment future treatments of sight-threatening microbial keratitis." | 3.80 | In vitro and in vivo evaluation of novel ciprofloxacin-releasing silicone hydrogel contact lenses. ( Hui, A; Jones, L; Willcox, M, 2014) |
| "To analyse the spectrum of bacterial keratitis isolates and their in vitro antibiotic susceptibilities over a 10-year period in Oxford, UK; and to compare the in vitro efficacy of ciprofloxacin with that of the combination of gentamicin and cefuroxime over the same period." | 3.77 | In vitro antibiotic susceptibility patterns of bacterial keratitis isolates in Oxford, UK: a 10-year review. ( Bowler, IC; Hornby, SJ; Orlans, HO, 2011) |
| " aureus keratitis, following the treatments, the median number of CFU of recoverable bacteria for chlorhexidine (n = 10), ciprofloxacin (n = 12), tobramycin/cefazolin (n = 12), and controls (n = 10) was 1." | 3.74 | A comparison of topical chlorhexidine, ciprofloxacin, and fortified tobramycin/cefazolin in rabbit models of Staphylococcus and Pseudomonas keratitis. ( Bouchard, CS; Bu, P; Carey, R; Riske, PS; Zaya, NE, 2007) |
| "To report a case of microbial keratitis caused by Nocardia transvalensis with resistance to amikacin." | 3.74 | Nocardia transvalensis resistant to amikacin: an unusual cause of microbial keratitis. ( Pandya, VB; Petsoglou, C, 2008) |
| "Both moxifloxacin and ciprofloxacin performed significantly better than control in the treatment of Pseudomonas aeruginosa keratitis (P=0." | 3.73 | Comparative efficacy of topical moxifloxacin versus ciprofloxacin and vancomycin in the treatment of P. aeruginosa and ciprofloxacin-resistant MRSA keratitis in rabbits. ( Aliprandis, E; Ciralsky, J; Herling, I; Katz, HR; Lai, H, 2005) |
| "Taurolidine is a broad-spectrum, non antibiotic antimicrobial agent, not previously tested against the common causes of bacterial keratitis." | 3.73 | Effectiveness of topical taurolidine versus ciprofloxacin, ofloxacin, and fortified cefazolin in a rabbit Staphylococcus aureus keratitis model. ( Gurkan, T; Oguz, E; Oguz, H; Ozbilge, H, 2005) |
| "Occurrence of a white precipitate of the corneal surface was recorded among 624 patients with presumed bacterial keratitis who were treated with topical ciprofloxacin 0." | 3.72 | Corneal ciprofloxacin precipitation during bacterial keratitis. ( Abshire, RL; Wilhelmus, KR, 2003) |
| " aureus to many antibiotics including ciprofloxacin and highlights the need for an alternative to ciprofloxacin monotherapy for the treatment of staphylococcal keratitis." | 3.72 | Clinical resistance of Staphylococcus keratitis to ciprofloxacin monotherapy. ( Garg, P; Rao, GN; Sharma, S; Sharma, V, 2004) |
| "The purpose of this study was to quantitatively compare, in a rabbit keratitis model, the levels of effectiveness of moxifloxacin, levofloxacin, and ciprofloxacin for the treatment of Staphylococcus aureus isolates of diverse antibiotic susceptibilities." | 3.72 | Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis. ( Dajcs, JJ; Girgis, DO; Marquart, ME; O'Callaghan, RJ; Thibodeaux, BA; Traidej, M, 2004) |
| " In this study we investigate the emergence of fluoroquinolone (ciprofloxacin, levofloxacin) resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis." | 3.72 | Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis. ( Alfonso, EC; Marangon, FB; Miller, D; Muallem, MS; Romano, AC, 2004) |
| "To determine the in vitro efficacy of levofloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae and Streptococcus viridans isolates recovered from clinical cases of keratitis and endophthalmitis." | 3.72 | Comparative in vitro activity of levofloxacin, ofloxacin, and ciprofloxacin against ocular streptococcal isolates. ( Alfonso, EC; Miller, D, 2004) |
| "Overall, moxifloxacin was the most effective of the four fluoroquinolones in reducing CFU/cornea in the rabbit model of gram-negative keratitis." | 3.72 | Quantitative comparison of fluoroquinolone therapies of experimental gram-negative bacterial keratitis. ( Caballero, AR; Dajcs, JJ; Girgis, DO; Marquart, ME; O'Callaghan, RJ; Thibodeaux, BA, 2004) |
| "The fourth-generation fluoroquinolone, gatifloxacin, is an effective prophylaxis against the development of keratitis after lamellar keratectomy in rabbits with an organism resistant to methicillin, levofloxacin, and ciprofloxacin." | 3.72 | Fluoroquinolone therapy in multiple-drug resistant staphylococcal keratitis after lamellar keratectomy in a rabbit model. ( Carpenter, TR; Kaufman, MB; McDonnell, PJ; Sarayba, MA; Sweet, PM; Taban, M; Tungsiripat, T, 2003) |
| "Lomefloxacin was compared with ciprofloxacin in different rabbit keratitis models." | 3.71 | Lomefloxacin is an effective treatment of experimental bacterial keratitis. ( Gordon, YJ; Kowalski, RP; Romanowski, EG; Yates, KA, 2001) |
| "Although patients ofNocardia keratitis may respond to other antibiotics, amikacin appears to be a drug of choice." | 3.71 | Treatment and outcome of nocardia keratitis. ( Garg, P; Rao, GN; Sharma, S; Sridhar, MS, 2001) |
| "We compared levofloxacin with ciprofloxacin and ofloxacin using the in vitro susceptibilities of Staphylococcus aureus (SA) and Pseudomonas aeruginosa (PA) keratitis isolates." | 3.71 | An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa. ( Gordon, YJ; Husted, RC; Karenchak, LM; Kowalski, RP; Pandya, AN; Ritterband, DC; Romanowski, EG; Shah, MK, 2001) |
| "By use of the in vitro antimicrobial susceptibility test, 22 cases of keratitis caused by ciprofloxacin-resistant Pseudomonas were identified." | 3.70 | Ciprofloxacin-resistant Pseudomonas keratitis. ( Garg, P; Rao, GN; Sharma, S, 1999) |
| "Topical treatment of experimental Staphylococcus keratitis with ciprofloxacin-PSS, ciprofloxacin, or ofloxacin was effective." | 3.70 | Effectiveness of ciprofloxacin-polystyrene sulfonate (PSS), ciprofloxacin and ofloxacin in a Staphylococcus keratitis model. ( Engel, LS; Green, LC; Hill, JM; Moreau, JM; O'Callaghan, RJ, 1998) |
| "Ciprofloxacin and prednisolone, but not an aminoglycoside and dexamethasone, were previously found to be effective in killing bacteria and reducing inflammation for the treatment of Pseudomonas keratitis." | 3.69 | Effectiveness of specific antibiotic/steroid combinations for therapy of experimental Pseudomonas aeruginosa keratitis. ( Callegan, MC; Engel, LS; Hill, JM; Hobden, JA; O'Callaghan, RJ; Reidy, JJ, 1995) |
| "36%) tobramycin for the treatment of methicillin-sensitive and methicillin-resistant Staphylococcus aureus keratitis during early and late stages of infection." | 3.69 | Ciprofloxacin versus tobramycin for the treatment of staphylococcal keratitis. ( Callegan, MC; Engel, LS; Hill, JM; O'Callaghan, RJ, 1994) |
| "To compare the efficacy of ciprofloxacin hydrochloride ointment with that of ciprofloxacin drops for treatment of experimental Pseudomonas keratitis, rabbit eyes were infected by intrastromal injection of 10(3) colony-forming units (CFU) log-phase P." | 3.68 | Ciprofloxacin ointment versus ciprofloxacin drops for therapy of experimental Pseudomonas keratitis. ( Hill, JM; Hobden, JA; Insler, MS; O'Callaghan, RJ, 1993) |
| "A rabbit model of Staphylococcus aureus keratitis was developed to study the chemotherapeutic efficacy of ciprofloxacin, vancomycin, and cefazolin." | 3.68 | Topical antibiotic therapy for the treatment of experimental Staphylococcus aureus keratitis. ( Callegan, MC; Hill, JM; Hobden, JA; Insler, MS; O'Callaghan, RJ, 1992) |
| "Studies using ciprofloxacin for the therapy of experimental aminoglycoside-resistant keratitis caused by Pseudomonas aeruginosa were conducted using transcorneal iontophoresis as the drug-delivery system." | 3.68 | Ciprofloxacin iontophoresis for aminoglycoside-resistant pseudomonal keratitis. ( Hill, JM; Hobden, JA; Insler, MS; O'Callaghan, RJ; Reidy, JJ, 1990) |
| "36% tobramycin in two experimental models of keratitis, using a methicillin-sensitive strain of Staphylococcus aureus and an aminoglycoside-sensitive strain of Pseudomonas aeruginosa, respectively." | 3.68 | Topical ciprofloxacin versus topical fortified antibiotics in rabbit models of Staphylococcus and Pseudomonas keratitis. ( Cohen, KL; Lauffenburger, MD, 1993) |
| "Ciprofloxacin is a fluoroquinolone antimicrobial agent inhibiting bacterial DNA gyrase, with good in vitro and in vivo activity against many Gram-positive and Gram-negative ocular pathogens." | 2.68 | Clinical evaluation of ciprofloxacin ophthalmic solution in the treatment of refractory bacterial keratitis. ( Chang, SW; Hu, FR; Tsai, AC; Tseng, MC, 1995) |
| "chelonei keratitis are reviewed." | 2.39 | Mycobacterium chelonei keratitis: a case report and review of previously reported cases. ( Broadway, DC; Eykyn, SJ; Kerr-Muir, MG; Pambakian, H, 1994) |
| "Ciprofloxacin is a potent fluoroquinolone antibiotic with in vitro activity against many significant gram-positive and gram-negative ocular pathogens." | 2.38 | Insights from experimental data on ciprofloxacin in the treatment of bacterial keratitis and ocular infections. ( Cokingtin, CD; Hyndiuk, RA, 1991) |
| " Besides, it is very necessary to improve the bioavailability of drugs by enhancing the ocular surface adhesion and corneal permeability." | 1.91 | Multifunctional Polymer Vesicles for Synergistic Antibiotic-Antioxidant Treatment of Bacterial Keratitis. ( Chen, Q; Chen, Y; Duan, Y; Han, X; Lin, Q; Liu, L; Shen, L; Shi, L, 2023) |
| "Cefazolin resistance was seen in 13." | 1.72 | Corynebacterium Keratitis: Pure Versus Mixed Infection and Antibiotic Susceptibility Patterns From Different Tertiary Eye Care Centers. ( Das, S; Gunasekaran, R; Mitra, S; Mohamed, A; Prajna, L; Prajna, NV; Sharma, S; Soni, T, 2022) |
| "Nocardia interface keratitis is a rare entity, which can occur after DMEK." | 1.51 | Management of Nocardia Interface Keratitis After Descemet Membrane Endothelial Keratoplasty. ( Chandrika, TN; Katta, KR; Mansoori, T; Reddy, AK; Srirampur, A, 2019) |
| "Gatifloxacin showed lower resistance levels than moxifloxacin." | 1.38 | [In vitro antibiotic susceptibility to fluoroquinolones]. ( Galvis, V; Rey, JJ; Tello, A; Villareal, D; Wong, CA, 2012) |
| "Mycobacterium keratitis is a potentially vision-threatening complication after LASIK." | 1.33 | Mycobacterium keratitis after laser in situ keratomileusis. ( Chen, YF; Hsiao, CH; Lin, KK; Yang, KS, 2005) |
| "Ciprofloxacin is a fluoroquinolone antibiotic with broad spectrum bactericidal activity." | 1.29 | The effectiveness of two ciprofloxacin formulations for experimental Pseudomonas and Staphylococcus keratitis. ( Callegan, MC; Engel, LS; Folkens, AT; Hill, JM; O'Callaghan, RJ; Shimomura, Y, 1996) |
| "Ciprofloxacin was significantly more effective than norfloxacin in reducing the number of bacteria per cornea (P less than 0." | 1.28 | Quinolones in collagen shields to treat aminoglycoside-resistant pseudomonal keratitis. ( Hill, JM; Hobden, JA; Insler, MS; O'Callaghan, RJ; Reidy, JJ, 1990) |
| "Ciprofloxacin is a new quinolone antibiotic that is highly active in vitro against Pseudomonas aeruginosa." | 1.27 | Topical ciprofloxacin treatment of Pseudomonas keratitis in rabbits. ( Dick, JD; Gottsch, JD; O'Brien, TP; Sawusch, MR, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.06) | 18.7374 |
| 1990's | 33 (35.11) | 18.2507 |
| 2000's | 38 (40.43) | 29.6817 |
| 2010's | 13 (13.83) | 24.3611 |
| 2020's | 9 (9.57) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, Y | 1 |
| Carion, TW | 2 |
| Ebrahim, AS | 2 |
| Sosne, G | 2 |
| Berger, EA | 2 |
| Soni, T | 1 |
| Gunasekaran, R | 1 |
| Das, S | 1 |
| Mitra, S | 1 |
| Prajna, NV | 1 |
| Prajna, L | 1 |
| Sharma, S | 5 |
| Mohamed, A | 1 |
| Pearce, JG | 1 |
| Essex, RW | 1 |
| Maddess, T | 1 |
| Romano, V | 1 |
| Bignotti, S | 1 |
| Forbice, E | 1 |
| Piccinelli, G | 1 |
| Caruso, A | 1 |
| Semeraro, F | 1 |
| Khan, M | 2 |
| Ma, K | 1 |
| Wan, I | 1 |
| Willcox, MD | 2 |
| Parmar, GS | 1 |
| Meena, AK | 1 |
| Borde, P | 1 |
| Prasad, S | 1 |
| Chen, Q | 1 |
| Han, X | 1 |
| Liu, L | 1 |
| Duan, Y | 1 |
| Chen, Y | 1 |
| Shi, L | 1 |
| Lin, Q | 1 |
| Shen, L | 1 |
| Fejes, I | 1 |
| Garcia-Hermosa, P | 1 |
| Bodin, A | 1 |
| Alluri, S | 1 |
| Ebrahim, T | 1 |
| Parker, T | 1 |
| Burns, J | 1 |
| Batlle-Ferrando, S | 1 |
| Peraza-Nieves, JE | 1 |
| Carreras-Castañer, X | 1 |
| Marin-Martinez, S | 1 |
| Miguel, L | 1 |
| Srirampur, A | 1 |
| Mansoori, T | 1 |
| Reddy, AK | 1 |
| Katta, KR | 1 |
| Chandrika, TN | 1 |
| Tosco-Núñez, T | 1 |
| Bolaños-Rivero, M | 1 |
| Herman, E | 1 |
| Pérez-Álvarez, J | 1 |
| Abdelkader, H | 1 |
| Mansour, HF | 1 |
| Li, SA | 1 |
| Liu, J | 1 |
| Xiang, Y | 1 |
| Wang, YJ | 1 |
| Lee, WH | 1 |
| Zhang, Y | 1 |
| Hui, A | 1 |
| Willcox, M | 1 |
| Jones, L | 1 |
| Davaran, S | 1 |
| Lotfipour, F | 1 |
| Sedghipour, N | 1 |
| Sedghipour, MR | 1 |
| Alimohammadi, S | 1 |
| Salehi, R | 1 |
| Pandya, VB | 1 |
| Petsoglou, C | 1 |
| Diec, J | 1 |
| Carnt, N | 1 |
| Tilia, D | 1 |
| Evans, V | 1 |
| Rao, V | 1 |
| Ozkan, J | 1 |
| Holden, BA | 2 |
| Sengupta, J | 1 |
| Khetan, A | 1 |
| Saha, S | 1 |
| Ganguly, A | 1 |
| Pal, D | 1 |
| Subrayan, V | 1 |
| Peyman, M | 1 |
| Lek Yap, S | 1 |
| Mohamed Ali, NA | 1 |
| Devi, S | 1 |
| Orlans, HO | 1 |
| Hornby, SJ | 1 |
| Bowler, IC | 1 |
| Westermeyer, HD | 1 |
| Hendrix, DV | 1 |
| Ward, DA | 1 |
| Cox, SK | 1 |
| Wong, CA | 1 |
| Galvis, V | 1 |
| Tello, A | 1 |
| Villareal, D | 1 |
| Rey, JJ | 1 |
| Venkata, N | 1 |
| Gora, R | 1 |
| Chhabra, R | 1 |
| Aasuri, MK | 1 |
| Tungsiripat, T | 1 |
| Sarayba, MA | 2 |
| Kaufman, MB | 1 |
| Sweet, PM | 2 |
| Taban, M | 2 |
| Carpenter, TR | 1 |
| McDonnell, PJ | 2 |
| Lomholt, JA | 1 |
| Kilian, M | 1 |
| Wilhelmus, KR | 1 |
| Abshire, RL | 1 |
| Marangon, FB | 1 |
| Miller, D | 2 |
| Muallem, MS | 1 |
| Romano, AC | 1 |
| Alfonso, EC | 2 |
| Dajcs, JJ | 3 |
| Thibodeaux, BA | 3 |
| Marquart, ME | 3 |
| Girgis, DO | 2 |
| Traidej, M | 2 |
| O'Callaghan, RJ | 14 |
| Caballero, AR | 1 |
| Rhee, MK | 1 |
| Kowalski, RP | 4 |
| Romanowski, EG | 4 |
| Mah, FS | 2 |
| Ritterband, DC | 2 |
| Gordon, YJ | 5 |
| Sharma, V | 1 |
| Garg, P | 3 |
| Rao, GN | 4 |
| Sankaridurg, PR | 1 |
| Sweeney, DF | 1 |
| Stretton, S | 1 |
| Naduvilath, TJ | 1 |
| Aliprandis, E | 1 |
| Ciralsky, J | 1 |
| Lai, H | 1 |
| Herling, I | 1 |
| Katz, HR | 1 |
| Yang, KS | 1 |
| Chen, YF | 1 |
| Lin, KK | 1 |
| Hsiao, CH | 1 |
| Oguz, H | 1 |
| Ozbilge, H | 1 |
| Oguz, E | 1 |
| Gurkan, T | 1 |
| Shamie, N | 1 |
| Reiser, BJ | 1 |
| Graff, JM | 1 |
| Kesler-Diaz, A | 1 |
| Osann, KE | 1 |
| Duran, N | 2 |
| Koc, A | 1 |
| Oksuz, H | 2 |
| Tamer, C | 2 |
| Akaydin, Y | 1 |
| Kozlu, T | 1 |
| Celik, M | 1 |
| Hoffman, PM | 1 |
| Poon, A | 1 |
| Snibson, GR | 1 |
| Donnenfeld, RS | 1 |
| Perry, HD | 1 |
| Solomon, R | 1 |
| Jensen, HG | 1 |
| Stein, J | 1 |
| Snyder, RW | 1 |
| Wittpenn, JR | 1 |
| Donnenfeld, ED | 1 |
| Dhaliwal, DK | 1 |
| Yates, KA | 2 |
| Onlen, Y | 1 |
| Altug, ME | 1 |
| Yakan, S | 1 |
| Su, PY | 1 |
| Hu, FR | 3 |
| Chen, YM | 1 |
| Han, JH | 1 |
| Chen, WL | 1 |
| Suman, G | 1 |
| Sabitha, K | 1 |
| Jamil, K | 1 |
| Woodward, M | 1 |
| Randleman, JB | 1 |
| Symes, RJ | 1 |
| Catt, CJ | 1 |
| Males, JJ | 1 |
| Bu, P | 1 |
| Riske, PS | 1 |
| Zaya, NE | 1 |
| Carey, R | 1 |
| Bouchard, CS | 1 |
| Al-Shakarchi, F | 1 |
| Afshari, NA | 1 |
| Ma, JJ | 1 |
| Duncan, SM | 1 |
| Pineda, R | 1 |
| Starr, CE | 1 |
| Decroos, FC | 1 |
| Johnson, CS | 1 |
| Adelman, RA | 1 |
| Diamond, JP | 1 |
| White, L | 1 |
| Leeming, JP | 1 |
| Bing Hoh, H | 1 |
| Easty, DL | 1 |
| Engel, LS | 5 |
| Callegan, MC | 4 |
| Hobden, JA | 8 |
| Reidy, JJ | 5 |
| Hill, JM | 11 |
| Broadway, DC | 1 |
| Kerr-Muir, MG | 1 |
| Eykyn, SJ | 1 |
| Pambakian, H | 1 |
| Probst, LE | 1 |
| Brewer, LV | 1 |
| Hussain, Z | 1 |
| Tokarewicz, AC | 1 |
| Lin, R | 2 |
| Holland, GN | 2 |
| Helm, CJ | 2 |
| Elias, SJ | 1 |
| Berlin, OG | 2 |
| Bruckner, DA | 2 |
| Lauffenburger, MD | 1 |
| Cohen, KL | 1 |
| Hwang, DG | 1 |
| Biswell, R | 1 |
| Insler, MS | 5 |
| Tsai, AC | 1 |
| Tseng, MC | 1 |
| Chang, SW | 1 |
| Behrens-Baumann, W | 1 |
| Folkens, AT | 1 |
| Shimomura, Y | 1 |
| Kaufman, SC | 1 |
| Laird, JA | 1 |
| Cooper, R | 1 |
| Beuerman, RW | 1 |
| Huang, SC | 1 |
| Soong, HK | 1 |
| Chang, JS | 1 |
| Liang, YS | 1 |
| Luh, KT | 1 |
| Karenchak, LM | 2 |
| Beatty, S | 1 |
| Chawdhary, S | 1 |
| Moreau, JM | 2 |
| Green, LC | 1 |
| Horgan, SE | 1 |
| Matheson, MM | 1 |
| McLOUGHLIN-Borlace, L | 1 |
| Dart, JK | 1 |
| McElvanney, AM | 1 |
| Lema, I | 1 |
| Gómez-Torreiro, M | 1 |
| Rodríguez-Ares, MT | 1 |
| Sridhar, MS | 1 |
| Pinna, A | 1 |
| Sechi, LA | 1 |
| Zanetti, S | 1 |
| Usai, D | 1 |
| Delogu, G | 1 |
| Cappuccinelli, P | 1 |
| Carta, F | 1 |
| Pandya, AN | 1 |
| Husted, RC | 1 |
| Shah, MK | 1 |
| Tabin, G | 1 |
| Danenhower, C | 1 |
| Reardon, D | 1 |
| Dimmig, J | 1 |
| McCormick, G | 1 |
| Austin, MS | 1 |
| Stroman, DW | 1 |
| Yeoh, J | 1 |
| Moshegov, CN | 1 |
| Suresh, PS | 1 |
| Rootman, DS | 1 |
| Hagenah, M | 1 |
| Forman, K | 1 |
| Cokingtin, CD | 1 |
| Hyndiuk, RA | 1 |
| Leibowitz, HM | 1 |
| O'Brien, TP | 1 |
| Sawusch, MR | 1 |
| Dick, JD | 1 |
| Gottsch, JD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Two Phase Clinical Study of the Impact of Contact Lenses and Solutions on Corneal Structure[NCT00804999] | 51 participants (Actual) | Interventional | 2008-11-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Looking for cell density (NCT00804999)
Timeframe: baseline and 2 hours
| Intervention | cells/mm^3 (Mean) | |
|---|---|---|
| Baseline | Two hours | |
| Non Contact Wearing Using Clear Care | 85 | 87 |
| Overnight Soaking in Optifree | 49 | 51 |
| Overnight Soaking in Optifree Replinish | 63 | 61 |
| Overnight Soaking With Renu | 66 | 65 |
5 reviews available for ciprofloxacin and Keratitis
| Article | Year |
|---|---|
The clinical treatment of bacterial keratitis: A review of drop instillation regimes.
Topics: Ciprofloxacin; Eye Infections, Bacterial; Fluoroquinolones; Humans; Keratitis; Ofloxacin | 2022 |
Keratitis Caused by Candida parapsilosis and Subsequent Corynebacterium macginleyi Infection: Case Report and Short Review.
Topics: Aged; Anti-Bacterial Agents; Antifungal Agents; Candida parapsilosis; Candidiasis; Ciprofloxacin; Co | 2020 |
Review of resistance of ocular isolates of Pseudomonas aeruginosa and staphylococci from keratitis to ciprofloxacin, gentamicin and cephalosporins.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cephalosporins; Ciprofloxacin; Drug Resistance, Bacter | 2011 |
Mycobacterium chelonei keratitis: a case report and review of previously reported cases.
Topics: Ciprofloxacin; Contact Lenses; Cornea; Erythromycin; Female; Humans; Imipenem; Keratitis; Keratoplas | 1994 |
Insights from experimental data on ciprofloxacin in the treatment of bacterial keratitis and ocular infections.
Topics: Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; Eye Diseases; Humans; Keratitis; Ps | 1991 |
5 trials available for ciprofloxacin and Keratitis
| Article | Year |
|---|---|
Microbial keratitis in prospective studies of extended wear with disposable hydrogel contact lenses.
Topics: Adolescent; Adult; Anti-Infective Agents; Bacteria; Ciprofloxacin; Contact Lenses, Extended-Wear; Co | 2005 |
Clinical evaluation of ciprofloxacin ophthalmic solution in the treatment of refractory bacterial keratitis.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Child; Ciprofloxacin; Eye Infections, Bacterial; Fem | 1995 |
[Ciprofloxacin eyedrops. Ciprofloxacin for topical therapy].
Topics: Ciprofloxacin; Conjunctivitis; Eye Diseases; Humans; Keratitis; Ophthalmic Solutions | 1995 |
Topical ciprofloxacin for treating nontuberculous mycobacterial keratitis.
Topics: Administration, Topical; Adolescent; Adult; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; | 1998 |
Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for treatment of bacterial keratitis.
Topics: Bacterial Infections; Chemical Precipitation; Ciprofloxacin; Cornea; Crystallization; Eye Diseases; | 1991 |
84 other studies available for ciprofloxacin and Keratitis
| Article | Year |
|---|---|
Adjunctive Thymosin Beta-4 Treatment Influences MΦ Effector Cell Function to Improve Disease Outcome in
Topics: Animals; Ciprofloxacin; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Inflammation; | 2021 |
Corynebacterium Keratitis: Pure Versus Mixed Infection and Antibiotic Susceptibility Patterns From Different Tertiary Eye Care Centers.
Topics: Anti-Bacterial Agents; Cefazolin; Ciprofloxacin; Coinfection; Corynebacterium; Eye Infections, Bacte | 2022 |
What empiric treatment should be given for suspected bacterial keratitis in Northern Italy?
Topics: Anti-Bacterial Agents; Bacteria; Ciprofloxacin; Eye Infections, Bacterial; Humans; Keratitis; Microb | 2022 |
Ciprofloxacin resistance and tolerance of Pseudomonas aeruginosa ocular isolates.
Topics: Agar; Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Gentamicins; Humans; Imipenem; Keratitis; L | 2023 |
Microbial keratitis and antibiotic sensitivity patterns: A retrospective analysis at a tertiary center in Central India.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Erythromycin; Eye Infections, Bacterial; Humans; Keratitis; Le | 2023 |
Multifunctional Polymer Vesicles for Synergistic Antibiotic-Antioxidant Treatment of Bacterial Keratitis.
Topics: Animals; Anti-Bacterial Agents; Antioxidants; Ciprofloxacin; Eye Infections, Bacterial; Keratitis; M | 2023 |
Antimicrobial Effects of Thymosin Beta-4 and Ciprofloxacin Adjunctive Therapy in
Topics: Anti-Bacterial Agents; Ciprofloxacin; Cornea; Drug Synergism; Epithelial Cells; Humans; Keratitis; L | 2020 |
Crystalline corneal deposits after one month of ciprofloxacin treatment for bacterial keratitis.
Topics: Aged; Anti-Bacterial Agents; Chemical Precipitation; Ciprofloxacin; Cornea; Crystallization; Female; | 2019 |
Management of Nocardia Interface Keratitis After Descemet Membrane Endothelial Keratoplasty.
Topics: Administration, Ophthalmic; Aged; Anti-Bacterial Agents; Atropine; Ciprofloxacin; Combined Modality | 2019 |
[Keratitis due to Moraxella lacunata: a case report].
Topics: Anti-Bacterial Agents; Botulinum Toxins; Ciprofloxacin; Conjunctivitis; Eye Diseases; Female; Humans | 2013 |
Comparative studies for ciprofloxacin hydrochloride pre-formed gels and thermally triggered (in situ) gels: in vitro and in vivo appraisal using a bacterial keratitis model in rabbits.
Topics: Animals; Anti-Bacterial Agents; Carboxymethylcellulose Sodium; Ciprofloxacin; Cornea; Delayed-Action | 2015 |
Therapeutic potential of the antimicrobial peptide OH-CATH30 for antibiotic-resistant Pseudomonas aeruginosa keratitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antimicrobial Cation | 2014 |
In vitro and in vivo evaluation of novel ciprofloxacin-releasing silicone hydrogel contact lenses.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Coated Materials, Biocompatible; Contact Lenses, Exte | 2014 |
Preparation and in vivo evaluation of in situ gel system as dual thermo-/pH-responsive nanocarriers for sustained ocular drug delivery.
Topics: Administration, Ophthalmic; Anti-Bacterial Agents; Ciprofloxacin; Drug Carriers; Gels; Humans; Kerat | 2015 |
Nocardia transvalensis resistant to amikacin: an unusual cause of microbial keratitis.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Multiple, Ba | 2008 |
Prompt diagnosis and treatment of microbial keratitis in a daily wear lens.
Topics: Administration, Topical; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Contact Lenses; | 2009 |
Bacterial keratitis after manual descemet stripping endothelial keratoplasty--a different pathophysiology?
Topics: Aged; Anti-Infective Agents; Ciprofloxacin; Corneal Transplantation; Descemet Membrane; Dexamethason | 2010 |
Assessment of polymerase chain reaction in the detection of pseudomonas aeruginosa in contact lens-induced severe infectious keratitis.
Topics: Adult; Ceftazidime; Ciprofloxacin; Contact Lenses; Diagnosis, Differential; DNA, Bacterial; Dose-Res | 2010 |
In vitro antibiotic susceptibility patterns of bacterial keratitis isolates in Oxford, UK: a 10-year review.
Topics: Anti-Bacterial Agents; Bacteria; Cefuroxime; Ciprofloxacin; Drug Resistance, Microbial; England; Eye | 2011 |
Tear, cornea, and aqueous humor concentrations of ciprofloxacin and moxifloxacin after topical ocular application in ophthalmologically normal horses.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aqueous Humor; Aza Compounds; Ciprofloxacin | 2011 |
[In vitro antibiotic susceptibility to fluoroquinolones].
Topics: Acanthamoeba Keratitis; Anti-Bacterial Agents; Aza Compounds; Body Fluids; Ciprofloxacin; Colombia; | 2012 |
Clinical presentation of microbial keratitis with daily wear frequent-replacement hydrogel lenses: a case series.
Topics: Adolescent; Adult; Aeromonas; Anti-Infective Agents; Ciprofloxacin; Contact Lenses, Hydrophilic; Eye | 2002 |
Fluoroquinolone therapy in multiple-drug resistant staphylococcal keratitis after lamellar keratectomy in a rabbit model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Corneal Stroma; Disease Mode | 2003 |
Ciprofloxacin susceptibility of Pseudomonas aeruginosa isolates from keratitis.
Topics: Anti-Infective Agents; Ciprofloxacin; DNA, Bacterial; Drug Resistance, Bacterial; Eye Infections, Ba | 2003 |
Corneal ciprofloxacin precipitation during bacterial keratitis.
Topics: Adolescent; Adult; Age Factors; Aged; Anti-Infective Agents; Chemical Precipitation; Child; Ciproflo | 2003 |
Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis.
Topics: Anti-Infective Agents; Ciprofloxacin; Conjunctivitis, Bacterial; Cross-Sectional Studies; Drug Resis | 2004 |
Comparative in vitro activity of levofloxacin, ofloxacin, and ciprofloxacin against ocular streptococcal isolates.
Topics: Anti-Infective Agents; Ciprofloxacin; Endophthalmitis; Humans; Keratitis; Levofloxacin; Microbial Se | 2004 |
Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Cornea; Drug Resistance, Bacterial; Fl | 2004 |
Quantitative comparison of fluoroquinolone therapies of experimental gram-negative bacterial keratitis.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Colony Count, Microbial; Cornea; Eye I | 2004 |
A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Colony Count, Microbial; Cornea; Disease Models, Anim | 2004 |
Clinical resistance of Staphylococcus keratitis to ciprofloxacin monotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxa | 2004 |
Comparative efficacy of topical moxifloxacin versus ciprofloxacin and vancomycin in the treatment of P. aeruginosa and ciprofloxacin-resistant MRSA keratitis in rabbits.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Colony Count, | 2005 |
Mycobacterium keratitis after laser in situ keratomileusis.
Topics: Administration, Topical; Adult; Amikacin; Anti-Bacterial Agents; Ciprofloxacin; Cornea; Drug Therapy | 2005 |
Effectiveness of topical taurolidine versus ciprofloxacin, ofloxacin, and fortified cefazolin in a rabbit Staphylococcus aureus keratitis model.
Topics: Administration, Topical; Animals; Anti-Infective Agents, Local; Cefazolin; Ciprofloxacin; Colony Cou | 2005 |
Fluoroquinolone therapy in Mycobacterium chelonae keratitis after lamellar keratectomy.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Cornea; Corneal Transplantat | 2005 |
The protective role of topical propolis on experimental keratitis via nitric oxide levels in rabbits.
Topics: Administration, Topical; Animals; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Ci | 2006 |
Nocardia keratitis in a contact lens wearer.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Contact Lenses, Extended-Wear; Drug Therapy, Combinatio | 2005 |
A comparison of gatifloxacin to ciprofloxacin in the prophylaxis of Streptococcus pneumoniae in rabbits in a LASIK model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Cornea; Disease Models, Animal; Eye Infections, Bacte | 2006 |
Role of topical fluoroquinolones on the pathogenesis of diffuse lamellar keratitis in experimental in vivo studies.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Corneal Stroma; Disease Models, Animal; Endotoxins; F | 2006 |
Comparative trial of different anti-bacterial combinations with propolis and ciprofloxacin on Pseudomonas keratitis in rabbits.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Colony Count, Microbial; Corneal Opacity; Dexamethaso | 2007 |
Dendritiform cells found in central cornea by in-vivo confocal microscopy in a patient with mixed bacterial keratitis.
Topics: Adult; Bacteria; Ciprofloxacin; Contact Lenses, Hydrophilic; Dendritic Cells; Drug Therapy, Combinat | 2006 |
Mutation in mexR-gene leading to drug resistance in corneal keratitis in human.
Topics: Amino Acid Sequence; Anti-Infective Agents; Bacterial Proteins; Base Sequence; Ciprofloxacin; Drug R | 2006 |
Bilateral methicillin-resistant Staphylococcus aureus keratitis after photorefractive keratectomy.
Topics: Ciprofloxacin; Eye Infections, Bacterial; Female; Humans; Keratitis; Lasers, Excimer; Methicillin Re | 2007 |
Diffuse lamellar keratitis associated with gonococcal keratoconjunctivitis 3 years after laser in situ keratomileusis.
Topics: Adult; Anti-Bacterial Agents; Ceftriaxone; Ciprofloxacin; Corneal Stroma; Doxycycline; Drug Therapy, | 2007 |
A comparison of topical chlorhexidine, ciprofloxacin, and fortified tobramycin/cefazolin in rabbit models of Staphylococcus and Pseudomonas keratitis.
Topics: Administration, Topical; Animals; Anti-Infective Agents, Local; Cefazolin; Chlorhexidine; Ciprofloxa | 2007 |
Initial therapy for suppurative microbial keratitis in Iraq.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Therapy, Combination; Eye Infections, Bacterial; Eye Infe | 2007 |
Trends in resistance to ciprofloxacin, cefazolin, and gentamicin in the treatment of bacterial keratitis.
Topics: Anti-Bacterial Agents; Cefazolin; Ciprofloxacin; Drug Resistance, Bacterial; Eye Infections, Bacteri | 2008 |
Topical 0.3% ciprofloxacin, norfloxacin, and ofloxacin in treatment of bacterial keratitis: a new method for comparative evaluation of ocular drug penetration.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Chromatography, High Pressure Liquid; Ciprofloxac | 1995 |
Effectiveness of specific antibiotic/steroid combinations for therapy of experimental Pseudomonas aeruginosa keratitis.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Colony Count, Microbial; Cornea; Dexamethasone; Disea | 1995 |
Treatment of Mycobacterium chelonae keratitis with amikacin, doxycycline and topical ciprofloxacin.
Topics: Administration, Topical; Amikacin; Ciprofloxacin; Doxycycline; Drug Therapy, Combination; Eye Infect | 1994 |
Ciprofloxacin versus tobramycin for the treatment of staphylococcal keratitis.
Topics: Animals; Ciprofloxacin; Colony Count, Microbial; Corneal Stroma; Drug Administration Schedule; Eye I | 1994 |
Comparative efficacy of topical ciprofloxacin for treating Mycobacterium fortuitum and Mycobacterium chelonae keratitis in an animal model.
Topics: Administration, Topical; Animals; Ciprofloxacin; Colony Count, Microbial; Disease Models, Animal; Ey | 1994 |
Age and therapeutic outcome of experimental Pseudomonas aeruginosa keratitis treated with ciprofloxacin, prednisolone, and flurbiprofen.
Topics: Aging; Animals; Aqueous Humor; Biological Assay; Ciprofloxacin; Cornea; Drug Therapy, Combination; F | 1993 |
Comparison of topical antibiotics for treating Mycobacterium fortuitum keratitis in an animal model.
Topics: Administration, Topical; Amikacin; Animals; Ciprofloxacin; Clarithromycin; Colony Count, Microbial; | 1993 |
Topical ciprofloxacin versus topical fortified antibiotics in rabbit models of Staphylococcus and Pseudomonas keratitis.
Topics: Administration, Topical; Animals; Cefazolin; Ciprofloxacin; Colony Count, Microbial; Cornea; Disease | 1993 |
Ciprofloxacin therapy of Mycobacterium chelonae keratitis.
Topics: Amikacin; Ciprofloxacin; Female; Humans; Keratitis; Middle Aged; Mycobacterium chelonae; Mycobacteri | 1993 |
Ciprofloxacin ointment versus ciprofloxacin drops for therapy of experimental Pseudomonas keratitis.
Topics: Animals; Ciprofloxacin; Eye Infections, Bacterial; Keratitis; Ointments; Ophthalmic Solutions; Pseud | 1993 |
Absorption of topically administered ciprofloxacin, ofloxacin and gentamicin in the inflamed rabbit eye.
Topics: Absorption; Administration, Topical; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aqueous | 1996 |
The effectiveness of two ciprofloxacin formulations for experimental Pseudomonas and Staphylococcus keratitis.
Topics: Animals; Anti-Infective Agents; Benzalkonium Compounds; Chelating Agents; Ciprofloxacin; Colony Coun | 1996 |
Diagnosis of bacterial contact lens related keratitis with the white-light confocal microscope.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Contact Lenses, Extended-Wear; Cornea; Eye Infections, | 1996 |
Non-tuberculous mycobacterial keratitis: a study of 22 cases.
Topics: Adult; Aged; Amikacin; Anti-Bacterial Agents; Ciprofloxacin; Eye Injuries; Female; Follow-Up Studies | 1996 |
Consultation section. Refractive surgical problem.
Topics: Ciprofloxacin; Contact Lenses; Corneal Injuries; Corneal Topography; Eye Injuries; Humans; Keratitis | 1998 |
Comparison of ciprofloxacin and ofloxacin using human corneal susceptibility levels.
Topics: Anti-Infective Agents; Biological Availability; Ciprofloxacin; Colony Count, Microbial; Cornea; Gram | 1998 |
Necrotizing sclerokeratitis following uncomplicated cataract surgery.
Topics: Abscess; Aged; Anti-Infective Agents; Cataract Extraction; Ciprofloxacin; Conjunctival Diseases; Cor | 1998 |
Effectiveness of ciprofloxacin-polystyrene sulfonate (PSS), ciprofloxacin and ofloxacin in a Staphylococcus keratitis model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Cornea; Disease Models, Anim | 1998 |
Use of a low nutrient culture medium for the identification of bacteria causing severe ocular infection.
Topics: Aged; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Ciprofloxacin; Clarithro | 1999 |
Ciprofloxacin-resistant Pseudomonas keratitis.
Topics: Adolescent; Adult; Anti-Infective Agents; Child; Ciprofloxacin; Drug Resistance, Microbial; Drug The | 1999 |
Hypopyon keratitis in corneal epithelial basement membrane dystrophy.
Topics: Adult; Anti-Infective Agents; Bacterial Infections; Basement Membrane; Ciprofloxacin; Corneal Diseas | 1999 |
Comamonas acidovorans keratitis in a hydrogel contact lens wearer.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Contact Lenses, Extended-Wear; Delftia acidovorans; Eye | 2001 |
Lomefloxacin is an effective treatment of experimental bacterial keratitis.
Topics: Administration, Topical; Animals; Anti-Infective Agents; Bacteria; Ciprofloxacin; Colony Count, Micr | 2001 |
Treatment and outcome of nocardia keratitis.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; E | 2001 |
Bacillus cereus keratitis associated with contact lens wear.
Topics: Bacillaceae Infections; Bacillus cereus; Ciprofloxacin; Conjunctiva; Contact Lens Solutions; Contact | 2001 |
An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa.
Topics: Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Drug Resistance, Microbial; Eye Infec | 2001 |
Opportunistic Roseomonas keratitis.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Eye Infections, Bacterial; Female; Gr | 2001 |
Effectiveness of ciprofloxacin and ofloxacin in a prophylaxis model of Staphylococcus keratitis.
Topics: Animals; Anti-Infective Agents; Antibiotic Prophylaxis; Ciprofloxacin; Colony Count, Microbial; Corn | 2001 |
Delayed diffuse lamellar keratitis after laser in situ keratomileusis.
Topics: Administration, Topical; Anti-Infective Agents; Anti-Inflammatory Agents; Ciprofloxacin; Cornea; Dex | 2001 |
Bilateral infectious keratitis after a laser in situ keratomileusis enhancement procedure.
Topics: Adult; Cefazolin; Ciprofloxacin; Cornea; Drug Therapy, Combination; Eye Infections, Bacterial; Femal | 2002 |
Topical antibiotic therapy for the treatment of experimental Staphylococcus aureus keratitis.
Topics: Animals; Cefazolin; Ciprofloxacin; Colony Count, Microbial; Disease Models, Animal; Eye Infections, | 1992 |
Ciprofloxacin and prednisolone therapy for experimental Pseudomonas keratitis.
Topics: Administration, Topical; Animals; Ciprofloxacin; Colony Count, Microbial; Corneal Stroma; Disease Mo | 1992 |
The efficacy of topical ciprofloxacin and norfloxacin in the treatment of experimental Pseudomonas keratitis.
Topics: Administration, Topical; Animals; Ciprofloxacin; Colony Count, Microbial; Keratitis; Norfloxacin; Ps | 1991 |
Ophthalmic ciprofloxacin.
Topics: Ciprofloxacin; Conjunctivitis, Bacterial; Drug Resistance, Microbial; Eye Infections, Bacterial; Hum | 1991 |
Quinolones in collagen shields to treat aminoglycoside-resistant pseudomonal keratitis.
Topics: Animals; Ciprofloxacin; Collagen; Colony Count, Microbial; Cornea; Drug Resistance, Microbial; Eye I | 1990 |
Ciprofloxacin iontophoresis for aminoglycoside-resistant pseudomonal keratitis.
Topics: Aminoglycosides; Animals; Aqueous Humor; Ciprofloxacin; Colony Count, Microbial; Drug Resistance, Mi | 1990 |
Topical ciprofloxacin treatment of Pseudomonas keratitis in rabbits.
Topics: Administration, Topical; Animals; Aqueous Humor; Ciprofloxacin; Cornea; Keratitis; Ophthalmic Soluti | 1988 |